These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back

cnbc2021-05-27

Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

152

Report

Comment（32）

banditmojo
·2021-05-28
Syros already up over 30% in 2 days..
Reply
Like
Report
All in Tesla
·2021-05-27
I’m sure ARK funds will perform in the coming years!! Innovation is the future ?
Reply
3
Report
燃烧吧我的小宇宙
·2021-05-27
??
Reply
Like
Report
ILFTS
·2021-05-27
Which is the one?
Reply
Like
Report
DZJ1976
·2021-05-27
It works until it doesn't
Reply
Like
Report
Fold Replies
- NEWBIE:
  hahaha so right
  2021-05-27
  Reply
  Report
lzh77
·2021-05-27
Please comment
Reply
1
Report
Fold Replies
- lzh77:
  ok
  2021-05-27
  Reply
  Report
- AndrewL:
  Done. pls respone back. thx
  2021-05-27
  Reply
  Report
lzh77
·2021-05-27
Which is your favourite
Reply
Like
Report
OCA
·2021-05-27
[財迷]
Reply
Like
Report
Kel9670ong
·2021-05-27
Cathie wood are EFT of high risk high risk
Reply
2
Report
Fold Replies
- NEWBIE:
  I should read up on her
  2021-05-27
  Reply
  Report
- jamjam:
  ok
  2021-05-27
  Reply
  Report
- Kel9670ong:
  yes all stocks holding are arkk
  2021-05-27
  Reply
  Report
4ZOEYS
·2021-05-27
Becareful of her, whatever stock she bought, need to avoid. Dyodd
Reply
3
Report
Stevenoh
·2021-05-27
Short now!!!
Reply
1
Report
Fold Replies
- Irenelim85:
  ??
  2021-05-27
  Reply
  Report
UTOtrader
·2021-05-27
Hahahaha.....
Reply
2
Report
Fold Replies
- UTOtrader:
  wat do u think leh, hahaha
  2021-05-27
  Reply
  Report
- Alicia Ling:
  你4个哈哈是在幸灾乐祸ARK跌到那么惨吗？
  2021-05-27
  Reply
  Report
MarketPulse
·2021-05-27
I was waiting for Ark investment below $100 and buy in. It recovered, still very strong ?
Reply
Like
Report
Fold Replies
- jamjam:
  okok
  2021-05-27
  Reply
  Report
koolgal
·2021-05-27
Keeping a close eye on Cathie's stock movements. Please like and comment. Thanks
Reply
1
Report
Fold Replies
- koolgal:
  Something to do.
  2021-05-27
  Reply
  Report
- JY00:
  Really?
  2021-05-27
  Reply
  Report
Hunter88
·2021-05-27
Buy ARKK?
Reply
Like
Report
Fold Replies
- WCS1981:
  I will research before i buy anything. I do not accord too much weight to the performance in 2020 as those who bought during the dip generally made a killing in 2020.
  2021-05-27
  Reply
  Report
KITkat
·2021-05-27
Believe?! Make it happen, please!!!
Reply
1
Report
Sushi__
·2021-05-27
Hmm
Reply
1
Report
Chaishen
·2021-05-27
Pls buy so I can run away LOL
Reply
Like
Report
Fold Replies
- AzriTan:
  Lol
  2021-05-27
  Reply
  Report
- KITkat:
  Same here, LOL
  2021-05-27
  Reply
  Report
frusty
·2021-05-27
I see. Like and comment
Reply
2
Report
Fold Replies
- frusty:
  wow
  2021-05-27
  Reply
  Report
Bluewhale
·2021-05-27
Believe her?? Whatever she say is after she already bought.
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1162725526?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-27 08:41","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1162725526","market":"us","top_or_hot":-1,"title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","media":"cnbc","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SURF","symbol_name":"Surface Oncology","start_time":0,"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","article_id":"1162725526","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","pubTimestamp":1622076098,"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SURF":"Surface Oncology","NIU":"小牛电动","GH":"Guardant Health Inc.","SYRS":"Syros Pharmaceuticals Inc.","TWLO":"Twilio Inc","AMZN":"亚马逊","RPTX":"Repare Therapeutics Inc.","CGEN":"Compugen医疗","PSNL":"Personalis","ARKK":"ARK Innovation ETF","ACCD":"Accolade, Inc.","CDXS":"Codexis","TDY":"Teledyne Technologies Inc","ONEM":"1Life Healthcare, Inc.","CSTL":"Castle Biosciences, Inc."},"translate_title":"这些都是华尔街认为最有可能卷土重来的Cathie Wood股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NIU":0.9,"TWLO":0.9,"TDY":0.9,"SYRS":0.9,"SURF":0.9,"SI":0.9,"RPTX":0.9,"PSNL":0.9,"ONEM":0.9,"ACCD":0.9,"GH":0.9,"CSTL":0.9,"CGEN":0.9,"CDXS":0.9,"BLI":0.9,"ARKK":0.9,"AMZN":0.9},"content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":135113737,"gmtCreate":1622143069629,"gmtModify":1704180236369,"author":{"id":"3584572574469601","authorId":"3584572574469601","name":"banditmojo","avatar":"https://static.tigerbbs.com/06d55c3b93452705221082ab6c8d1dd2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3584572574469601","authorIdStr":"3584572574469601"},"htmlText":"Syros already up over 30% in 2 days..","listText":"Syros already up over 30% in 2 days..","text":"Syros already up over 30% in 2 days..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/135113737","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132708768,"gmtCreate":1622112325954,"gmtModify":1704179668399,"author":{"id":"3577580366301047","authorId":"3577580366301047","name":"All in Tesla","avatar":"https://community-static.tradeup.com/news/8db11f6e6a9a2a52850e734188850dc2","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"3577580366301047","authorIdStr":"3577580366301047"},"htmlText":"I’m sure ARK funds will perform in the coming years!! Innovation is the future ?","listText":"I’m sure ARK funds will perform in the coming years!! Innovation is the future ?","text":"I’m sure ARK funds will perform in the coming years!! Innovation is the future ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132708768","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132465315,"gmtCreate":1622108046037,"gmtModify":1704179600438,"author":{"id":"3577973342242790","authorId":"3577973342242790","name":"燃烧吧我的小宇宙","avatar":"https://static.tigerbbs.com/f355f30467c97ea6ebb736238d0d3c62","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577973342242790","authorIdStr":"3577973342242790"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132465315","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132553475,"gmtCreate":1622102184397,"gmtModify":1704179486623,"author":{"id":"3562921834163798","authorId":"3562921834163798","name":"ILFTS","avatar":"https://static.tigerbbs.com/4e8eb567072e2b7f82acb5ce6ecab099","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562921834163798","authorIdStr":"3562921834163798"},"htmlText":"Which is the one?","listText":"Which is the one?","text":"Which is the one?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132553475","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132523582,"gmtCreate":1622101265846,"gmtModify":1704179473405,"author":{"id":"3577722120895602","authorId":"3577722120895602","name":"DZJ1976","avatar":"https://static.tigerbbs.com/f0cb3bd8146604a31cbb6b27cf53752e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577722120895602","authorIdStr":"3577722120895602"},"htmlText":"It works until it doesn't&nbsp;","listText":"It works until it doesn't&nbsp;","text":"It works until it doesn't","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132523582","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4470373,"gmtCreate":1622113872425,"gmtModify":1680791330103,"authorId":3573124416025977,"author":{"id":3573124416025977,"idStr":"3573124416025977","authorId":3573124416025977,"name":"NEWBIE","avatar":"https://static.tigerbbs.com/3efe20248e6d34805e6c7befc3ae66a0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132523582,"type":1,"supId":0,"prevId":0,"content":"hahaha so right","text":"hahaha so right","html":"hahaha so right"}],"langContent":"EN"},{"id":132584794,"gmtCreate":1622099722718,"gmtModify":1704179453946,"author":{"id":"3581654499912172","authorId":"3581654499912172","name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581654499912172","authorIdStr":"3581654499912172"},"htmlText":"Please comment","listText":"Please comment","text":"Please comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/132584794","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4468908,"gmtCreate":1622103070343,"gmtModify":1680791304314,"authorId":3581654499912172,"author":{"id":3581654499912172,"idStr":"3581654499912172","authorId":3581654499912172,"name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.12","exceedPercentage":"60.35%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132584794,"type":1,"supId":4468500,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":4468500,"gmtCreate":1622099878109,"gmtModify":1680791302154,"authorId":3571815908504020,"author":{"id":3571815908504020,"idStr":"3571815908504020","authorId":3571815908504020,"name":"AndrewL","avatar":"https://static.tigerbbs.com/f45655eaaab14f0b61c554eea4d95ca7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132584794,"type":1,"supId":0,"prevId":0,"content":"Done. pls respone back. thx","text":"Done. pls respone back. thx","html":"Done. pls respone back. thx"}],"langContent":"EN"},{"id":132584098,"gmtCreate":1622099658314,"gmtModify":1704179452325,"author":{"id":"3581654499912172","authorId":"3581654499912172","name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581654499912172","authorIdStr":"3581654499912172"},"htmlText":"Which is your favourite","listText":"Which is your favourite","text":"Which is your favourite","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132584098","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132586889,"gmtCreate":1622099340341,"gmtModify":1704179448277,"author":{"id":"3575424174048922","authorId":"3575424174048922","name":"OCA","avatar":"https://static.tigerbbs.com/9ed67c34f4cdc380936cc9945710bf76","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3575424174048922","authorIdStr":"3575424174048922"},"htmlText":"[財迷]&nbsp;","listText":"[財迷]&nbsp;","text":"[財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132586889","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":132244754,"gmtCreate":1622094995078,"gmtModify":1704179369600,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Cathie wood are EFT of high risk high risk","listText":"Cathie wood are EFT of high risk high risk","text":"Cathie wood are EFT of high risk high risk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/132244754","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4470380,"gmtCreate":1622113915195,"gmtModify":1680791327916,"authorId":3573124416025977,"author":{"id":3573124416025977,"idStr":"3573124416025977","authorId":3573124416025977,"name":"NEWBIE","avatar":"https://static.tigerbbs.com/3efe20248e6d34805e6c7befc3ae66a0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132244754,"type":1,"supId":0,"prevId":0,"content":"I should read up on <u>her</u>","text":"I should read up on <u>her</u>","html":"I should read up on <u>her</u>"},{"id":4468157,"gmtCreate":1622097104601,"gmtModify":1680791295553,"authorId":3559204036277229,"author":{"id":3559204036277229,"idStr":"3559204036277229","authorId":3559204036277229,"name":"jamjam","avatar":"https://static.tigerbbs.com/6542201483b33e63d9036c1e565275b2","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132244754,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":4472733,"gmtCreate":1622126666277,"gmtModify":1663227448631,"authorId":3578468158955348,"author":{"id":3578468158955348,"idStr":"3578468158955348","authorId":3578468158955348,"name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132244754,"type":1,"supId":4470380,"prevId":0,"content":"yes all stocks holding are <u>arkk</u>","text":"yes all stocks holding are <u>arkk</u>","html":"yes all stocks holding are <u>arkk</u>"}],"langContent":"EN"},{"id":132264948,"gmtCreate":1622092572984,"gmtModify":1704179327461,"author":{"id":"3576159031156193","authorId":"3576159031156193","name":"4ZOEYS","avatar":"https://static.tigerbbs.com/485a6405c364ce85c22e81b2913d390f","vip":1,"hat":"https://static.tigerbbs.com/3b7820dfed76481d8dc4de6ac5a7a136","crmLevel":7,"crmLevelSwitch":1,"idStr":"3576159031156193","authorIdStr":"3576159031156193"},"htmlText":"Becareful of her, whatever stock she bought, need to avoid. Dyodd","listText":"Becareful of her, whatever stock she bought, need to avoid. Dyodd","text":"Becareful of her, whatever stock she bought, need to avoid. Dyodd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132264948","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132268190,"gmtCreate":1622092304310,"gmtModify":1704179322445,"author":{"id":"3580551463324218","authorId":"3580551463324218","name":"Stevenoh","avatar":"https://static.tigerbbs.com/2864e71b7de77c92cd605a0a430bc5f1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3580551463324218","authorIdStr":"3580551463324218"},"htmlText":"Short now!!!&nbsp;","listText":"Short now!!!&nbsp;","text":"Short now!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132268190","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4467568,"gmtCreate":1622092464165,"gmtModify":1680791287230,"authorId":3581905357038973,"author":{"id":3581905357038973,"idStr":"3581905357038973","authorId":3581905357038973,"name":"Irenelim85","avatar":"https://static.tigerbbs.com/90d775f1edd315221f691822d8f5dc28","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132268190,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":132260765,"gmtCreate":1622092073957,"gmtModify":1704179317580,"author":{"id":"3574547619690492","authorId":"3574547619690492","name":"UTOtrader","avatar":"https://static.tigerbbs.com/82be6befb29ac8516e463638d3f659d5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574547619690492","authorIdStr":"3574547619690492"},"htmlText":"Hahahaha.....","listText":"Hahahaha.....","text":"Hahahaha.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/132260765","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4467997,"gmtCreate":1622095764019,"gmtModify":1680791297026,"authorId":3574547619690492,"author":{"id":3574547619690492,"idStr":"3574547619690492","authorId":3574547619690492,"name":"UTOtrader","avatar":"https://static.tigerbbs.com/82be6befb29ac8516e463638d3f659d5","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132260765,"type":1,"supId":4467765,"prevId":0,"content":"wat do u think leh, <u>hahaha</u>","text":"wat do u think leh, <u>hahaha</u>","html":"wat do u think leh, <u>hahaha</u>"},{"id":4467765,"gmtCreate":1622093870915,"gmtModify":1680791279540,"authorId":3558680293731120,"author":{"id":3558680293731120,"idStr":"3558680293731120","authorId":3558680293731120,"name":"Alicia Ling","avatar":"https://static.tigerbbs.com/ca35384a8589b2187095e5d2d4706a00","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132260765,"type":1,"supId":0,"prevId":0,"content":"你4个哈哈是在幸灾乐祸ARK跌到那么惨吗？","text":"你4个哈哈是在幸灾乐祸ARK跌到那么惨吗？","html":"你4个哈哈是在幸灾乐祸ARK跌到那么惨吗？"}],"langContent":"EN"},{"id":132285309,"gmtCreate":1622091853901,"gmtModify":1704179313025,"author":{"id":"3577347851898435","authorId":"3577347851898435","name":"MarketPulse","avatar":"https://static.tigerbbs.com/d6b16f1b86e7977d1bb375d78b71b51d","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":1,"idStr":"3577347851898435","authorIdStr":"3577347851898435"},"htmlText":"I was waiting for Ark investment below $100 and buy in. It recovered, still very strong ?&nbsp;","listText":"I was waiting for Ark investment below $100 and buy in. It recovered, still very strong ?&nbsp;","text":"I was waiting for Ark investment below $100 and buy in. It recovered, still very strong ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132285309","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4468161,"gmtCreate":1622097118377,"gmtModify":1680791290943,"authorId":3559204036277229,"author":{"id":3559204036277229,"idStr":"3559204036277229","authorId":3559204036277229,"name":"jamjam","avatar":"https://static.tigerbbs.com/6542201483b33e63d9036c1e565275b2","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132285309,"type":1,"supId":0,"prevId":0,"content":"<u>okok</u>","text":"<u>okok</u>","html":"<u>okok</u>"}],"langContent":"EN"},{"id":132286122,"gmtCreate":1622091743066,"gmtModify":1704179310274,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Keeping a close eye on Cathie's stock movements.&nbsp; Please like and&nbsp;comment.&nbsp; Thanks","listText":"Keeping a close eye on Cathie's stock movements.&nbsp; Please like and&nbsp;comment.&nbsp; Thanks","text":"Keeping a close eye on Cathie's stock movements. Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/132286122","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4469549,"gmtCreate":1622107010576,"gmtModify":1680791321581,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.22","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":132286122,"type":1,"supId":4467697,"prevId":0,"content":"Something to do.","text":"Something to do.","html":"Something to do."},{"id":4467697,"gmtCreate":1622093303741,"gmtModify":1680791287999,"authorId":3581568450429470,"author":{"id":3581568450429470,"idStr":"3581568450429470","authorId":3581568450429470,"name":"JY00","avatar":"https://static.tigerbbs.com/b6e17ebb891eb376aff5c7eb5088602f","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132286122,"type":1,"supId":0,"prevId":0,"content":"Really?","text":"Really?","html":"Really?"}],"langContent":"EN"},{"id":132281978,"gmtCreate":1622091591794,"gmtModify":1704179307203,"author":{"id":"3568465315215545","authorId":"3568465315215545","name":"Hunter88","avatar":"https://static.tigerbbs.com/86703ca12fc27292ee7240b13fa4e166","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3568465315215545","authorIdStr":"3568465315215545"},"htmlText":"Buy ARKK?","listText":"Buy ARKK?","text":"Buy ARKK?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132281978","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4467493,"gmtCreate":1622091956789,"gmtModify":1680791281730,"authorId":3582764273979695,"author":{"id":3582764273979695,"idStr":"3582764273979695","authorId":3582764273979695,"name":"WCS1981","avatar":"https://static.tigerbbs.com/f98e28d5b1695429dd1657ecc78f93f5","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132281978,"type":1,"supId":0,"prevId":0,"content":"I will research before i buy anything. I do not accord too much weight to the performance in 2020 as those who bought during the dip generally made a killing in 2020. ","text":"I will research before i buy anything. I do not accord too much weight to the performance in 2020 as those who bought during the dip generally made a killing in 2020. ","html":"I will research before i buy anything. I do not accord too much weight to the performance in 2020 as those who bought during the dip generally made a killing in 2020. "}],"langContent":"EN"},{"id":132214004,"gmtCreate":1622091250508,"gmtModify":1704179300242,"author":{"id":"3577174452658160","authorId":"3577174452658160","name":"KITkat","avatar":"https://static.tigerbbs.com/8a71ab0dde411563f803aa81b1d189a8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3577174452658160","authorIdStr":"3577174452658160"},"htmlText":"Believe?! Make it happen, please!!!&nbsp;","listText":"Believe?! Make it happen, please!!!&nbsp;","text":"Believe?! Make it happen, please!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132214004","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132212917,"gmtCreate":1622091102739,"gmtModify":1704179297169,"author":{"id":"3576117016717305","authorId":"3576117016717305","name":"Sushi__","avatar":"https://static.tigerbbs.com/a0cf978c30326a9a36749f913b33ab2e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576117016717305","authorIdStr":"3576117016717305"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132212917","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":132216415,"gmtCreate":1622091083137,"gmtModify":1704179296846,"author":{"id":"3575102877976288","authorId":"3575102877976288","name":"Chaishen","avatar":"https://static.tigerbbs.com/b8bb167c6f990b4a02d66313039eb021","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":5,"crmLevelSwitch":1,"idStr":"3575102877976288","authorIdStr":"3575102877976288"},"htmlText":"Pls buy so I can run away LOL&nbsp;","listText":"Pls buy so I can run away LOL&nbsp;","text":"Pls buy so I can run away LOL","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/132216415","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4467402,"gmtCreate":1622091444020,"gmtModify":1680791284030,"authorId":3556009150724705,"author":{"id":3556009150724705,"idStr":"3556009150724705","authorId":3556009150724705,"name":"AzriTan","avatar":"https://static.itradeup.com/news/0cd0f245ac901c9a4590d4456d8fa63a","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.93%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132216415,"type":1,"supId":0,"prevId":0,"content":"Lol","text":"Lol","html":"Lol"},{"id":4467345,"gmtCreate":1622091222004,"gmtModify":1680791272949,"authorId":3577174452658160,"author":{"id":3577174452658160,"idStr":"3577174452658160","authorId":3577174452658160,"name":"KITkat","avatar":"https://static.tigerbbs.com/8a71ab0dde411563f803aa81b1d189a8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132216415,"type":1,"supId":0,"prevId":0,"content":"Same here, <u>LOL</u>","text":"Same here, <u>LOL</u>","html":"Same here, <u>LOL</u>"}],"langContent":"EN"},{"id":132216964,"gmtCreate":1622091060158,"gmtModify":1704179295878,"author":{"id":"3555119187338975","authorId":"3555119187338975","name":"frusty","avatar":"https://static.tigerbbs.com/46c85297aaa1b07647be4b2ca33ea8e8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3555119187338975","authorIdStr":"3555119187338975"},"htmlText":"I see. Like and comment","listText":"I see. Like and comment","text":"I see. Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132216964","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4467302,"gmtCreate":1622091073889,"gmtModify":1680791271456,"authorId":3555119187338975,"author":{"id":3555119187338975,"idStr":"3555119187338975","authorId":3555119187338975,"name":"frusty","avatar":"https://static.tigerbbs.com/46c85297aaa1b07647be4b2ca33ea8e8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":132216964,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"}],"langContent":"EN"},{"id":132218963,"gmtCreate":1622091013352,"gmtModify":1704179294908,"author":{"id":"3572745420946108","authorId":"3572745420946108","name":"Bluewhale","avatar":"https://static.tigerbbs.com/679f0a505c89407ddae8763e7c5e717e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3572745420946108","authorIdStr":"3572745420946108"},"htmlText":"Believe her??&nbsp;Whatever she say is after she already bought.&nbsp;","listText":"Believe her??&nbsp;Whatever she say is after she already bought.&nbsp;","text":"Believe her?? Whatever she say is after she already bought.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132218963","repostId":1162725526,"repostType":4,"repost":{"id":"1162725526","pubTimestamp":1622076098,"share":"https://ttm.financial/m/news/1162725526?lang=&edition=fundamental","pubTime":"2021-05-27 08:41","market":"us","language":"en","title":"These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back","url":"https://stock-news.laohu8.com/highlight/detail?id=1162725526","media":"cnbc","summary":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts","content":"<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These are the Cathie Wood stocks Wall Street believes have the best chance of roaring back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese are the Cathie Wood stocks Wall Street believes have the best chance of roaring back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 08:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","TDY":"Teledyne Technologies Inc","CSTL":"Castle Biosciences, Inc.","GH":"Guardant Health Inc.","CDXS":"Codexis","ONEM":"1Life Healthcare, Inc.","NIU":"小牛电动","SURF":"Surface Oncology","CGEN":"Compugen医疗","RPTX":"Repare Therapeutics Inc.","PSNL":"Personalis","ARKK":"ARK Innovation ETF","SYRS":"Syros Pharmaceuticals Inc.","AMZN":"亚马逊","ACCD":"Accolade, Inc."},"source_url":"https://www.cnbc.com/2021/05/26/cathie-wood-stocks-that-wall-street-believes-can-roar-back.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1162725526","content_text":"Popular fund manger Cathie Wood’s ETFs have been on shaky ground this year, but Wall Street analysts see the prospects improving for a bunch of her funds’ holdings.Shares of Wood’s flagshipARK Innovationare down more than 12% this year amid a rotation from growth stocks into value. The fear of rising interest rates in the first quarter and concerns about inflation this quarter have spurred weakness in Wood’s top holdings, especially the high profile names likeTeslaandTeladoc.Nearly $7 billion flowed out of ARK Innovation in 2021, according to FactSet.All of Wood’s other major ETFs, except ARK Autonomous Technology & Robotics, are in the red for the year. ARK Next Generation Internet ETF is down nearly 8% and ARK Genomic Revolution is down nearly 15%. ARK Fintech Innovation ETF has lost roughly 1.5% this year.However, lately some of the selling has stabilized, indicating a bottom could be in the cards for some of these innovation names.CNBC PRO screened for the Ark Invest-owned stocks that have the best chance of roaring back from their recent weakness, according to Wall Street analysts.The listed stocks are all holdings in one of Ark’s core ETFs. Plus, Wall Street expects these names to rally more than 20% in the next year, based on the stocks’ average 12-month price target from analysts.Lastly, the listed stocks have more than 80% of analysts assigning them a buy rating, with a minimum of five analysts covering the equity.Take a look at CNBC PRO’s list here.Syros PharmaceuticalsandCompugenare two of ARK Invest-held names that are universally loved on Wall Street. Both stocks have 100% of analysts calling them a buy.Analysts expect Syros Pharmaceuticals to gain nearly 230% in the next year and Compugen to rally more than 190% in the next 12 months.“We are buyers on recent weakness as Syros is trading at a current enterprise value of $142 million with a Phase III MDS asset and rich pipeline,” Piper Sandler analyst Edward Tenthoff said about the gene control therapy company. Shares of the stock are down more than 53% in 2021.Compugen is down roughly 40% this year, but Stifel told clients that the cancer immunology company “commands significant scarcity value, in our opinion – particularly given confirmation of COM701-mediated efficacy as both a single-agent (important for any immunotherapy target) and in combination with PD-1 inhibition in heavily pre-treated patients across a spectrum historically challenging-to-treat tumor types.”ARK Genomic Revolution purchased 36,907 shares ofCodexis— a stock on CNBC PRO’s list — worth about $728,500, based on the stock’s price of $19.74 per share at Tuesday’s closing.Surface Oncology,Berkeley Lights,Personalis, 1Life Healthcare,Silvergate CapitalandTwilioalso made CNBC PRO’s list.Amazonalso made the list of stocks that are expected to bounce back. Shares of Amazon are trading around the flatline for the year, but following the company’sblowout earningswhere sales surged 44%, analysts expect it to rally more than 30% in the next 12 months.ARK Genomic Revolution also purchased 8,755 shares of Repare Therapeutics on Tuesday. The purchase was worth about $284,000 based on Repare’s closing price of $32.45 per share.Teledyne Technologies,Castle Biosciences, Ping An Healthcare and Technology,Niu Technologies,Guardant HealthandAccoladealso earned spots on CNBC PRO’s list.Wood made a name for herself after ARK Innovation returned nearly 150% in 2020. Her funds have seen more than $15 billion in fund flows in the past year, according to FactSet.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":152,"commentSize":32,"repostSize":0,"favoriteSize":4,"likeStatus":false,"favoriteStatus":false}}